Paul Tudor Jones Travere Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 37,386 shares of TVTX stock, worth $307,312. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,386Holding current value
$307,312% of portfolio
0.0%Shares
11 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$64.1 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$61.7 Million0.79% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$60.6 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$54.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$51.5 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $528M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...